Current Studies
HVTN 405/HPTN 1901
Study Title: Characterizing SARS-CoV-2-specific immunity in convalescent individuals Study summary: The primary objectives of the study are: 1) To identify serologic reactivities that differentiate SARS-CoV-2 infection from vaccination; 2) To develop a …
HVTN
More about this study »HVTN 140/HPTN 101
Study Title: A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV-uninfected adult participants Study summary: The …
HVTN
More about this study »HVTN 805/HPTN 093
Study Title: Antiretroviral analytical treatment interruption (ATI) to assess immunologic and virologic responses in participants who initiated ART in early HIV infection after having received VRC01 or placebo in HVTN 703/HPTN 081. Study summary: This …
HVTN
More about this study »IMPAACT 2028
Study Title: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV Protocol summary: IMPAACT 2028 is an observational study to characterize a cohort of children who may participate in future research …
IMPAACT
More about this study »IMPAACT 2026
Study Title: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum Protocol summary: IMPAACT 2026 is a Phase IV, prospective, pharmacokinetic (PK) study of selected antiretroviral (ARV) and anti-tuber …
IMPAACT
More about this study »IMPAACT 2016
Study Title: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings Protocol summary: IMPAACT 2016 is a multi-site, two-arm, randomized, controlled study preceded by a feas …
IMPAACT
More about this study »IMPAACT 2010/VESTED
Study Title: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants Protocol summary: IMPAACT 2010 is a Phase III, …
IMPAACT
More about this study »IMPAACT 2009
Study Title: Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants Protocol summary: IMPAACT 2009 is a para …
IMPAACT
More about this study »IMPAACT 2008
Study Title: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants Protocol summary: IMPAACT 2008 is a Phase I/II, multisite, ran …
IMPAACT
More about this study »IMPAACT 2001
Study Title: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection Protocol summary: IMPAAC …
IMPAACT
More about this study »P1112
Study Title: Open-Label, Dose-Escalating, Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous (SC) VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants Protocol summ …
IMPAACT
More about this study »P1093
Study Title: Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents Protocol summary: …
IMPAACT
More about this study »The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention
Study: The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention Study Title: Combined HIV Adolescent PrEP and Prevention: On Demand Pre-exposure Prophylaxis to Provide Protection from HIV in Men – Using Foreskin Tissue to Estimate Protection (Phase …
IMPAACT
More about this study »CONRAD / A Phase II Acceptability Study of Oral emtricitabine/tenofovir alafenamide (F/TAF) vs emtricitabine/tenofovir disoproxil fumarate (F/TDF) for the Prevention of HIV Acquisition in Adolescent Girls and Young Women (AGYW)
SUMMARY Primary Objective: Acceptability Acceptability: To explore user attitudes, beliefs, experiences, side effects on acceptability of study products Secondary Objective: Adherence Adherence: To explore subjective and objective adherence to study pr …
Non-Network
More about this study »DPP
Study Title: A randomized, crossover study to evaluate the acceptability of an over-encapsulated dual prevention pill (DPP capsule) containing pre-exposure prophylaxis (PrEP) and a combined oral contraceptive (COC) pill versus two separate tablets (PrE …
Non-Network
More about this study »HPTN 084
Study Title: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women. Protocol summary: HPTN 084 (The LIFE Study) is a study being done …
HPTN
More about this study »MTN 045
Study Title: Dual Purpose Prevention (DPP) Product Preferences among Couples Protocol summary: MTN-045 was a cross-sectional study that utilized questionnaires, including a Discrete-Choice Experiment (DCE) and joint decision task, to assess couples’ pr …
MTN
More about this study »MTN 043
Study Title: Phase 3B, Open-label, Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs Protocol summary: MTN-043 is a Phase 3B, open-label, randomized (3:1), multi-site, mother-infant pair P …
MTN
More about this study »MTN 042B
Study Title: Assessing Baseline Pregnancy Outcomes in Sub-Saharan Africa Protocol summary: MTN-042B was a cross-sectional chart review study designed to provide an estimate of pregnancy outcome frequency data (term delivery, preterm delivery, still bir …
MTN
More about this study »MTN 042 (DELIVER)
Study Title: Phase 3b, Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring (VR) and Oral TRUVADA Use in Pregnancy Protocol summary: MTN-042 is a Phase 3b, open-label, multi-site, randomized (2:1 in Cohorts 1-2 and 4:1 in Cohort 3) trial desi …
MTN
More about this study »MTN 034 (REACH)
Study Title: A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population Protocol summary: MTN- …
MTN
More about this study »A5349
Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial. Protocol summary: The purpose of this study is to determine whether one or two four-month regimens of tubercul …
ACTG
More about this study »A5381
Observational Cohort to Assess Therapeutic Efficacy And Emergence Of HIV Drug Resistance Following Initiation Of Tenofovir-Lamivudine-Dolutegravir (TLD) For First- Or Second-Line ART Protocol summary This is a study for people who have HIV and qualify …
ACTG
More about this study »A5379
B-Enhancement of HBV Vaccination in Persons Living with HIV (BEe-HIVe): Evaluation Of HEPLISAV-B Study summary A5379 is a study looking at hepatitis B vaccination in adults living with HIV. Hepatitis B is a serious viral infection that affects the live …
ACTG
More about this study »A5372
Drug-Drug Interactions Between Rifapentine and Dolutegravir In HIV/LTBI Co-Infected Individuals (RPT-DTG PK Study). Study summary The purpose of this research study is to see if taking medications to prevent tuberculosis (TB) affect the drug levels in …
ACTG
More about this study »A5354
This study evaluates whether starting antiretroviral drugs very early in HIV infection will limit the virus from getting into hidden areas of the body (reservoirs) and change how the immune system helps to control the virus. The study includes people w …
ACTG
More about this study »A5332 REPRIEVE Trial
Protocol summary: In this study, people between the ages of 40 and 75 with HIV will be randomized (like flipping a coin) to take the pill pitavastatin OR a placebo (non-active pill) to see if pitavastatin can help prevent heart disease and death in peo …
ACTG
More about this study »A5300B
Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Participants (PHOENIx). Protocol summary: This trial is of household contacts (HHC) at high risk for developing multidrug resistant tuberculosis (MDR-TB) which …
ACTG
More about this study »MTN 025 (HOPE)
A Phase 3B Open-Label Follow-on Trial to Assess the Continued Safety and Adherence to a Vaginal Ring Containing Dapivirine in Women (HOPE) Sponsors: Division of AIDS (DAIDS) Eunice Kennedy Shriver National Institute of Child Health and Development (NIC …
MTN
More about this study »HPTN 082
Evaluation of Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study Sponsors: Division of AIDS (DAIDS) National Institute of Allergy and Infectious Diseases (NIAID) National Institute of Mental health (NIMH) Nationa …
HPTN
More about this study »HVTN 703/HPTN 081 (AMP)
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in sub-Saharan Africa Sponsors: Division of AIDS (DAIDS) National Institute of Allergy and Infect …
HPTN
More about this study »P1115
Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof-of-Concept Study Sponsors: The National Institute of Allergy and Infectious Diseases (NIAD) The Eunice Kennedy Shriver National Institute of Child Heal …
IMPAACT
More about this study »P1078
A Phase IV Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety (Hepatotoxicity) of Immediate (Antepartum-Initiated) vs. Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High TB incidence Set …
IMPAACT
More about this study »MTN 016
(EMBRACE): HIV Prevention Agent Pregnancy Exposure Registry Sponsors: Division of AIDS, US National Institute of Allergy and Infectious Diseases (NIAID) US National Institutes of Health (NIH) Protocol Summary: EMBRACE is a prospective observational coh …
MTN
More about this study »MTN 015
An Observational Cohort Study of Women following HIV-1 Seroconversion in Microbicide Trials Sponsors: Division of AIDS, US National Institute of Allergy and Infectious Diseases (NIAID) US National Institutes of Health (NIH) Protocol Summary: MTN-015 is …
MTN
More about this study »A5263
A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource Limited Settings Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) The National Canc …
ACTG
More about this study »Completed Studies
MTN 032
Assessment of ASPIRE and HOPE Adherence Sponsors: Division of AIDS (DAIDS) National Institute of Allergy and Infectious Diseases (NIAID) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institute of Menta …
MTN
More about this study »HPTN 076
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre Exposure Prophylaxis (PrEP) Sponsors: Division of AIDS, US National Institute of Allergy and Infectious Diseases (NIAID) US National Institutes of Health (NI …
HPTN
More about this study »ZIM CHIC
HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas Sponsor: Bill & Melinda Gates Foundation, through a grant from McMagee-Women’s Research Institute and Foundation, University of Pittsburg Protoco …
Non-Network
More about this study »MTN 003B
Bone Mineral Density Substudy to MTN 003 (VOICE) Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS (DAIDS) US National Institutes of Health (NIH) Protocol Summary: MTN 003B is a substudy of MTN 003 (VOICE), whi …
MTN
More about this study »HPTN 052
A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples Sponsors: Division of AIDS, US National Institute of Al …
HPTN
More about this study »Non-Pneumatic Anti-Shock Garment (NASG), A First-Aid Device to Decrease Maternal Mortality from Obstetric Hemorrhage: A Cluster Randomized Trial
Sponsors: US National Institutes of Child Health and Human Development The Bill & Melinda Gates Foundation Protocol Summary: This study was a cluster randomized controlled trial to examine the effects of NASG application as a first-aid device at sa …
Non-Network
More about this study »A5185s
A Substudy of A5175: Effect of Initial Antiretroviral Treatment on Genital Compartment Virus in Individuals from Diverse Areas of the World Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5185s was a substud …
ACTG
More about this study »Disclosure Intervention for Zimbabwean Parents
Sponsor: US National Institutes of Health (NIH) Protocol Summary: 300 parents living with HIV (PLH) will be randomized into either an 1) experimental condition, a disclosure intervention or 2) attention control condition, a nutrition intervention. The …
Non-Network
More about this study »MTN 020 (ASPIRE)
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women (ASPIRE) Sponsors: Division of AIDS, US National Institute …
MTN
More about this study »MTN 003D
An Exploratory Study of Potential Sources of Efficacy Dilution in the VOICE Trial Sponsors: Division of AIDS, US National Institute of Allergy and Infectious Diseases (NIAID) US National Institutes of Health (NIH) Protocol Summary: MTN 003D is a qualit …
MTN
More about this study »P1104s
Longitudinal Developmental and Neuropsychological Assessments of HIV infected Participants of P1060 and HIV Uninfected Sponsors: US National Institute of Allergy and Infectious Diseases (NIAD) The Eunice Kennedy Shriver National Institute of Child Heal …
IMPAACT
More about this study »P1084s
Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMSE Protocol Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) The Eunice Kennedy …
IMPAACT
More about this study »1077BF – PROMISE
Promoting Maternal and Infant Survival Everywhere (PROMISE) Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Protocol Summary: 1077BF …
IMPAACT
More about this study »P1073
Study of Immune Reconstitution Inflammatory Syndrome (IRIS) for International Sites Initiating Highly Active Antiretroviral Therapy (HAART) in Infants and Children < 72 months of Age Sponsors: US National Institute of Allergy and Infectious Diseases …
IMPAACT
More about this study »P1072
Safety and Immunogenicity of a Live, Attenuated, Rotavirus Vaccine (ROTATEQTM) In HIV-Infected and Uninfected Children Born To HIV-Infected Mothers Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) The Eunice Kennedy Shriver Na …
IMPAACT
More about this study »P1070
Dose-Finding and Pharmacogenetic Study of Efavirenz in HIV-Infected and HIV/TB Co-Infected Infants and Children ≥ 3 Months to < 36 Months of Age Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) The Eunice Kennedy Shriver Na …
IMPAACT
More about this study »P1060
Phase II, Parallel, Randomized, Clinical Trials Comparing The Responses To Initiation of NNRTI-based Versus PI-Based Antiretroviral Therapy in HIV-Infected Infants Who Have And Have Not Previously Received Single Dose Nevirapine For Prevention of Mothe …
IMPAACT
More about this study »A5282
A Randomized, Phase II Trial to Compare an HPV Test-and-Treat Strategy to a Cytology-based Strategy for Prevention of CIN 2+ in HIV-infected Women Sponsor: US National institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5282 is a ra …
ACTG
More about this study »A5278
Pharmacology Substudies of A5263 and A5264 Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) The National Cancer Institute (NCI) National Institute on Dental Craniofacial Research (NIDCR) Protocol Summary: A5278 is designed to …
ACTG
More about this study »A5274
Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5274 is a randomized, open-label, phase IV strategy trial, where parti …
ACTG
More about this study »A5273
Mulitcenter Study of Options for SEcond-Line Effective Combination Therapy (SELECT) Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5273 is a phase III, dual-arm, open-label, randomized, non-inferiority stu …
ACTG
More about this study »A5265
A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Topical Gentian Violet to that of Nystatin Oral Suspension for the Treatment of OC in HIV-1 Infected Participants in Non-US Settings Sponsors: …
ACTG
More about this study »Establishment of Laboratory Reference Values for Harare, Chitungwiza, and Mutoko
Sponsor: US National Institutes of Health (NIH) Protocol Summary: This study sought to establish local reference values in order to enable accurate interpretation of laboratory data collected to support UZ-UCSF protocols. This was a community based, cr …
Non-Network
More about this study »An Acceptability and Safety Study of the Duet® Cervical Barrier and Gel Delivery System in Zimbabwe
Sponsors: US National Institutes of Health (NIH) The Bill & Belinda Gates Foundation Protocol Summary: Adherence problems with coitally dependent, female-initiated HIV prevention methods have contributed to several studies unable to establish effic …
Non-Network
More about this study »Linking Alcohol Use with HIV Risk Behavior and HIV Prevalence Among Beer Hall Patrons in Harare, Zimbabwe
Sponsor: US National Institutes of Health (NIH) Protocol Summary: In Harare, beer halls are among the few affordable recreation venues for men in low to medium income neighborhoods. They are well attended and ubiquitous institutions serving men’s needs …
Non-Network
More about this study »The Reliability of ACASI Data Collection in Zimbabwe
Sponsor: US National Institutes of Health (NIH) Protocol Summary: Research on the measurement of HIV risk demonstrates that interview mode can affect reporting; however, few studies have applied these findings to assessment sof hormonal contraceptive u …
Non-Network
More about this study »Diaphragm and Lubricant Gel for Prevention of HIV Acquisition in Southern African Women: A Randomized, Controlled Trial (MIRA)
Sponsor: The Bill and Melinda Gates Foundation Protocol Summary: MIRA was a multi-site, randomized, controlled study that sought to measure the effectiveness of the diaphragm, Replens gel and condoms versus condoms alone in preventing heterosexual acq …
Non-Network
More about this study »Oral Candidiasis Marker of HIV-Disease Progression Among Zimbabwean Women
Sponsor: US National Institutes of Health (NIH) Protocol Summary: To estimate oral disease prevalence among Zimbabwean women in relation to HIV serostatus and CD4 count, and to assess the agreement rate between oral soft tissue examination outcomes mea …
Non-Network
More about this study »Hormonal Contraception and the Risk of HIV-1 Acquisition Among Young Women in Uganda and Zimbabwe
Sponsors: US National Institutes of Health (NIH) Protocol Summary: Combined oral contraceptives (COC) and depot-medroxyprogesterone acetate (DMPA) are among the most widely used family planning methods; their effect on HIV acquisition is unknown. This …
Non-Network
More about this study »A Randomized, Controlled Safety Trial of the Diaphragm and Cellulose Sulfate Microbicide Gel in Sexually Active Women in Zimbabwe
Sponsor: CONRAD Protocol Summary: Cellulose sulfate (CS) was an antimicrobial and contraceptive agent. This study was designed with three arms: 1) diaphragm with 6% CS gel; 2) diaphragm with KY gel and; 3) CS gel alone. Participants were instructed to …
Non-Network
More about this study »Visual Inspection of the Cervix as a Primary Means of Cervical Cancer Screening: Results of a Pilot Study
Sponsor: US National Institutes of Health (NIH) Protocol Summary: The objective was to measure the effectiveness of unaided visual inspection (UVI) of the cervix as a primary means of cervical cancer screening. 1000 women attending primary health care …
Non-Network
More about this study »MTN 003 (VOICE)
Safety and effectiveness of Tenofovir 1% Gel,Tenofovir Disoproxil Fumarate Tablet and Emtricitabine/ Tenofovir Disoproxil Fumarate Tablet for the prevention of HIV infection in women Sponsors: Division of AIDS US National Institute of Allergy and Infec …
MTN
More about this study »HPTN/MTN 035
Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO2000/5 Gel (P) for the Prevention of HIV Infection in Women Sponsors: Division of AIDS, US National Institute of Allergy and Infectious Diseases (NIAID) Natio …
MTN
More about this study »Phase I Trial of the Topical Microbicide BufferGel
Sponsors: Division of AIDS, US National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH) Protocol Summary: To evaluate the safety of BufferGel, a spermicidal microbicide that acidifies semen and maintains the pro …
MTN
More about this study »P1060
Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV-Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mothe …
IMPAACT
More about this study »PEPFAR 046
Integrating Family Planning into PMTCT: A Novel Approach in Zimbabwe (A Substudy of HPTN/IMPAACT 046) Sponsors: US National Institutes of Health (NIH) PEPFAR Protocol Summary: PEPFAR 046 sought to understand the feasibility and short-term effects of an …
IMPAACT
More about this study »HPTN/IMPAACT 046
Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV Infected Women to Prevent Vertical HIV Transmission During Breastfeeding Sponsors: Division of AIDS, US National Institute of Allergy and I …
IMPAACT
More about this study »HPTN 043
A Phase III, Randomized, Controlled Trial of Community Mobilization, Mobile Testing, Same-Day Results, and Post-Testing Support for HIV in Sub-Saharan Africa and Thailand (Project Accept) Sponsor: US National Institute of Mental Health Protocol Summary …
HPTN
More about this study »HPTN 039
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir for the Reduction of HIV Acquisition Among High Risk HSV-2 Seropositive, HIV Seronegative Individuals Sponsors: Division of AIDS, US National Institute of Allergy and Infectio …
HPTN
More about this study »HIVNET/HPTN 023
Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants from Birth to 6 Months Sponsor: US National Institutes of Health (NIH) Protocol Summary: HIVNET 023 was a phase I/II, open-label, …
HPTN
More about this study »A5234
International Trial of Modified Directly Observed Therapy versus Self-Administered Therapy for Participants with First Virologic Failure on a Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Regimen Sponsor: US National Institut …
ACTG
More about this study »A5225
A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5225 was a phase I/II dose escalation and validat …
ACTG
More about this study »A5221
A Strategy Study of Immediate Versus Deferred initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis with CD4 Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID) Protoc …
ACTG
More about this study »A5208
Optimal Combination Therapy After Nevirapine Exposure (OCTANE) Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5208 was a phase III study that comprised of two randomized clinical trials that were conducted …
ACTG
More about this study »A5199
International Neuropsychological Assessment of Patients Initiating Antiretroviral Therapy in Resource-Limited Settings Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) US National Institute of Mental Health Summary: A5199 was …
ACTG
More about this study »A5190/P1054
Assessment of Safety and Toxicity among Infants Born To HIV-1-Infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID) Protocol Summary: A5190- …
ACTG
More about this study »HIVNET/HPTN 016A Substudy
Association of Sexually Transmitted Infections and HIV Among Women Attending the Condom Promotion and Counseling Study in Harare Sponsor: US National Institutes of Health (NIH) Protocol Summary: The aim of this substudy was to compare the prevalence of …
HPTN
More about this study »HIVNET/HPTN 016A
Condom Promotion and Counseling Sponsor: US National Institutes of Health (NIH) Protocol Summary: The aim of the study was to evaluate the effectiveness of condom promotion and counseling messages on uptake of condoms as a means to prevent HIV transmis …
HPTN
More about this study »A5264
A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy Versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource Limited Settings Sponsors: US National Institut …
ACTG
More about this study »A5199
International Neuropsychological Assessment of Patients Initiating Antiretroviral Therapy in Resource-Limited Settings Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID) US National Institute of Mental Health Summary: A5199 was …
ACTG
More about this study »A5175
A Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily PI & Once-Daily Non-NRTI – Containing Therapy Combinations for Initial Treatment of HIV-1 Infected individuals from Resource – Limited Settings (PEARLS) Trial …
ACTG
More about this study »
